TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00431743
Drug: Hydroxyethylstarch 130/0,4
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00044915
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients receive 1.25 mg of placebo
Study: NCT02785068
Drug: nal-IRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanoliposomal irinotecan
Study: NCT02785068
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: folinic acid
Study: NCT01059136
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unique 200mg IV dose of Potassium Canrenoate followed by 25 mg daily oral dose of Spironolactone for 6 months
Study: NCT01023724
Drug: Ketorolac Tromethamine 0.45%
Normalized name: KETOROLAC TROMETHAMINE 0.45%PF OPH 0.4ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acuvail to be given 1 drop BID for one day prior to surgery and then 1 drop BID post operatively for 14 days.
Study: NCT01023724
Drug: Bromfenac 0.09%
Normalized name: Bromfenac 0.09% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug given one drop BID for one day pre operatively and then BID for 14 days post operatively
Study: NCT04085913
Drug: Lidocaine Epinephrine
Normalized name: epinephrine / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincision injection, as is current practice
Study: NCT04085913
Drug: Bupivacaine Hydrochloride-EPINEPHrine
Normalized name: Bupivacaine Hydrochloride-Epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincision injection
Study: NCT04085913
Drug: Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preincison injection of lidocaine and epinephrine and a postincision injection of Exparel
Study: NCT03521245
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy regimen recommended for breast cancer
Study: NCT02212886
Drug: GA Depot 80 mg
Normalized name: methylPREDNISolone acetate 80 MG/ML [DEPO-Medrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recruitment completed
Study: NCT02212886
Drug: GA Depot 40 mg
Normalized name: methylPREDNISolone acetate 40 MG/ML [DEPO-Medrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recruitment completed
Study: NCT00747279
Drug: Intensive insulin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous regular insulin infusion will be adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 and 120 mg/dl. Patients will be submitted to capillary glycemic measurements every 2 hours. The insulin dose is adjusted according to an algorithm run by nurses and overseen by physicians. These patients will receive glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids.
Study: NCT00578695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT02317705
Drug: OTL38
Normalized name: Fluorodeoxyglucose F 18
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02800161
Drug: Maltose
Normalized name: Maltose
DrugBank: Maltose (DB03323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltose 70g/die
Study: NCT02258295
Drug: Intragel
Normalized name: TITANIUM DIOXIDE 63 mg in 1 mL / ZINC OXIDE 40 mg in 1 mL TOPICAL LOTION [INTRAL SENSITIVE SKIN ENVIRONMENTAL LIGHTWEIGHT SHIELD BROAD SPECTRUM SPF50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragel has an average molecular weight of 800-1200 kDaltons.
Study: NCT03385525
Drug: BIIB074
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT00033111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill manufactured to mimic cabergoline 05mg tablet
Study: NCT00148876
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 2500 mg/m² orally day 1-14 q day 22
Study: NCT03981627
Drug: ADO09 formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of ADO09 formulation
Study: NCT03981627
Drug: NovoRapid®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of insulin aspart
Study: NCT03761810
Drug: S6G5T-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day topical cream
Study: NCT03761810
Drug: S6G5T-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day topical cream
Study: NCT02922426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing for 21 consecutive days
Study: NCT01398748
Drug: Intranasal glutathione - (in)GSH
Normalized name: GSH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal glutathione-Tripeptide glutathione 100 mg/ml. 1 ml 3x per day TID X 12 weeks at 2100mg in 15 participants
Study: NCT01398748
Drug: Intranasal glutathione - (in)GSH
Normalized name: GSH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Glutathione-Tripeptide glutathione - 200mg/ml. 1 ml 3x per day TID X 12 weeks at 4200mg in 15 participants
Study: NCT01398748
Drug: Saline Intranasal Delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administration 1ml 3x/day 12 weeks in 15 participants
Study: NCT01049620
Drug: RAD001, Capecitabine, Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level -1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 5mg po qd D1-21~Dose level 1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 2 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3A : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 3B : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 4 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 5 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21
Study: NCT03038256
Drug: concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.~XELOX:~Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks~Surgery Procedure:~Total Mesorectal Excision
Study: NCT03038256
Drug: concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.~XELOX:~Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks~Surgery Procedure:~Total Mesorectal Excision
Study: NCT00138775
Drug: D-serine
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03545789
Drug: [18F]MNI-958
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.
Study: NCT03308253
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 120 mg tobramycin per patient
Study: NCT02395614
Drug: triple antibiotic irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: -triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.~80 mg of gentamicin in 500 mL of NS. If the patient is allergic to either component - the allergen will not be used in the solution - to irrigate one breast pocket
Study: NCT03772665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral tablet taken for 24 months
Study: NCT00811174
Drug: Octagam 10%
Normalized name: Octagam 10% Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)
Study: NCT01280695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsules
Study: NCT03268941
Drug: TAK-906 Maleate
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-906 Maleate Capsules
Study: NCT03268941
Drug: Metaclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaclopramide Tablets
Study: NCT03268941
Drug: TAK-906 Maleate Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-906 placebo-matching Capsules
Study: NCT02503501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacteriostatic 0.9% Sodium Chloride
Study: NCT02127476
Drug: KHK6640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose and multiple ascending doses administration
Study: NCT02127476
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose and multiple ascending doses administration
Study: NCT01740401
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This study consists of a Treatment Period, D1 Zofran 8mg pre-Cyclophosphamide 300mg/mg2 po and D3 Ipilimumab 10mg/kg iv wks 1,4,7 and 10; Tumor assessment at week 12; Follow-Up period weeks 13,16,and 20 with no treatment; Maintenance Period, D1 10mg/kg iv wks 24,36,48 and 60. Week 40=end of treatment; week 60=end of study
Study: NCT01455896
Drug: ITCA 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650
Study: NCT01996124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose, dry inhalation powder, hard capsules via breezhaler
Study: NCT01886469
Drug: HLD100-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine sulfate capsules, 30 mg, CII (25% SR, 30% pH coat, slow release; formulation B)
Study: NCT00364598
Drug: Anginera, a human tissue replacement therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00854139
Drug: Cyclophosphamide, anti-thymocyte globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 60 mg/kg IV on Day -5, -4 Anti-thymocyte globulin 20 mg/kg IV on Day -1, Day +1, +3, +5~Cyclosporine starting on Day -1 at 5 mg/kg daily I.V. and reduced to 3 mg/kg on Day +4, and adjusted to provide a trough whole blood concentration of 250-400 ng/mL. The route of administration will be changed to oral as soon as the patient is able to tolerate oral medications
Study: NCT03788967
Drug: Dummy Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy intravenous infusion.
Study: NCT01161537
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet.
Study: NCT03788967
Drug: Dummy tablets
Normalized name: cholecalciferol / tricalcium phosphate Chewable Tablet [Caltrate Gummy Bites]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy tablets orally.
Study: NCT00321464
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
Study: NCT02602119
Drug: OTL38
Normalized name: Fluorodeoxyglucose F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of OTL38 prior to surgery
Study: NCT04039737
Drug: Qingpeng Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
Study: NCT02245672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via the CRC749 and Diskus devices
Study: NCT01078363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of a placebo post heart Transplant for Blood pressure control.
Study: NCT00138632
Drug: PTK787
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visudyne® + PTK787, 500 mg/day
Study: NCT00138632
Drug: PTK787
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visudyne® + PTK787 1000 mg/day
Study: NCT00138632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visudyne® + Placebo
Study: NCT00415922
Drug: ELC200 (carbidopa+levodopa+entacapone)
Normalized name: carbidopa / entacapone / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03896945
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules
Study: NCT02347228
Drug: OB318 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral qd, at least 30 minutes before breakfast
Study: NCT03350737
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin i.v.
Study: NCT02688985
Drug: Methyloprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.
Study: NCT03967925
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg prednisolone tapering dose
Study: NCT04385342
Drug: HP-hMG
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ovarian stimulation by FSH followed by HMG versus FSH plus HMG
Study: NCT02702180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nebulizer solution for inhalation
Study: NCT03646474
Drug: saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the placebogroup, patients will receive a placebo of 100 mL 0.9% normal saline.
Study: NCT04321642
Drug: Entonox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entonox gas with mouth piece
Study: NCT04321642
Drug: Not receive Entonox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not receive any gas
Study: NCT00711971
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: control arm
Study: NCT02768519
Drug: OTS167IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: diluted to final concentration with cherry syrup
Study: NCT01446003
Drug: Placebo for MK-8457
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 x 10-mg capsule BID for 10 days
Study: NCT02632916
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid 0.025mg/kg at baseline, 6 months, 12 months and 18 months
Study: NCT00490555
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel 10 g
Study: NCT01815840
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib placebo orally once daily
Study: NCT01085877
Drug: estradiol, 25 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of vaginal tablet containing 25 mcg estradiol (Production site A) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site B)
Study: NCT01085877
Drug: estradiol, 25 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of vaginal tablet containing 25 mcg estradiol (Production site B) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site A)
Study: NCT02504580
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-011 (bupivacaine/meloxicam) by injection.
Study: NCT02504580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo by injection.
Study: NCT02504580
Drug: HTX-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-002, by injection or instillation (pooled).
Study: NCT02504580
Drug: HTX-011A
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-011A (bupivacaine/meloxicam) by injection.
Study: NCT02504580
Drug: HTX-011B
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.
Study: NCT02504580
Drug: HTX-009
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-009 by injection and instillation (combination).
Study: NCT00856544
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film coated tablet, 5 mg PO BID, 1 year
Study: NCT00856544
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film coated tablet, 10 mg PO BID, 1 year
Study: NCT00856544
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film coated tablet, 1 tablet PO BID, 3-6 months
Study: NCT02435927
Drug: ASLAN001+ CAPOX (Oxaliplatin, capecitabine)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ASLAN001 in combination with oxaliplatin and capecitabine
Study: NCT01055314
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01055314
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03057561
Drug: Cardiac MRI taken using contrast agent, Dotarem® (Gd-DOTA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadolinium based contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
Study: NCT03057561
Drug: Cardiac MRI with contrast agent, Gadovist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand of Gd-DO3A-butrol; contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
Study: NCT00568126
Drug: Maca Root
Normalized name: maca root
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g/day of Maca Root for 12 weeks.
Study: NCT00568126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo provided by research pharmacy daily for 12 weeks.
Study: NCT00444574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
Study: NCT02914665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intravenously once daily for 7 consecutive days
Study: NCT05316818
Drug: FOLFOXIRI Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triplet chemotherapy regimen consists from active three cytotoxic agents aiming to improve outcomes
Study: NCT02451293
Drug: Melatonin (N-acetyl-5-methoxytryptamine)
Normalized name: N-Acetyl-5-methoxytryptamine
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02451293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03369951
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline is a semisynthetic derivative of tetracycline and is indicated for the treatment of infections due to susceptible isolates of designated microorganisms.
Study: NCT01858740
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03371784
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: I.V. administration
Study: NCT03371784
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. administration
Study: NCT03971357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drops
Study: NCT00117039
Drug: Aranesp®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03927144
Drug: AMG334
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection
Study: NCT00254475
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03747679
Drug: bosunitib sorbitol
Normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 Mg of bosutinib sorbitol solution
Study: NCT04027751
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators administrated intravenously 0.9% saline solution as a placebo
Study: NCT00836810
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.
Study: NCT00271427
Drug: L-Selenomethionine
Normalized name: L-Selenomethionine Blend
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03897335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group will not receive any aminophylline treatments for the first post-op five days
Study: NCT00880217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule once daily for 42 days
Study: NCT00880217
Drug: JNJ-31001074 3 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-mg capsule once daily for 42 days
Study: NCT00880217
Drug: JNJ-31001074 1 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-mg capsule once daily for 42 days
Study: NCT00880217
Drug: JNJ-31001074 10 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg capsule once daily for 42 days
Study: NCT00234546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 injection at day 0. The study will last for 6 months in each patient.
Study: NCT00003515
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT02463383
Drug: Placebo tab
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo tablet is provided and an alcohol challenge (0.4g/kg bw) is given 30min later